Switch theme
Sign up to access all valuation multiples
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
1999
713
LTM Revenue $199M
LTM EBITDA $5.9M
$600M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Valneva has a last 12-month revenue (LTM) of $199M and a last 12-month EBITDA of $5.9M.
In the most recent fiscal year, Valneva achieved revenue of $190M and an EBITDA of $36.0M.
Valneva expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Valneva valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $199M | XXX | $190M | XXX | XXX | XXX |
| Gross Profit | $94.1M | XXX | $79.8M | XXX | XXX | XXX |
| Gross Margin | 47% | XXX | 42% | XXX | XXX | XXX |
| EBITDA | $5.9M | XXX | $36.0M | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | 19% | XXX | XXX | XXX |
| EBIT | -$19.7M | XXX | -$87.4M | XXX | XXX | XXX |
| EBIT Margin | -10% | XXX | -46% | XXX | XXX | XXX |
| Net Profit | -$46.8M | XXX | -$13.8M | XXX | XXX | XXX |
| Net Margin | -23% | XXX | -7% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $21.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Valneva's stock price is EUR 3 (or $3).
Valneva has current market cap of EUR 476M (or $535M), and EV of EUR 535M (or $600M).
See Valneva trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $600M | $535M | XXX | XXX | XXX | XXX | $-0.29 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Valneva has market cap of $535M and EV of $600M.
Valneva's trades at 3.2x EV/Revenue multiple, and 16.7x EV/EBITDA.
Equity research analysts estimate Valneva's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Valneva has a P/E ratio of -11.4x.
See valuation multiples for Valneva and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $535M | XXX | $535M | XXX | XXX | XXX |
| EV (current) | $600M | XXX | $600M | XXX | XXX | XXX |
| EV/Revenue | 3.0x | XXX | 3.2x | XXX | XXX | XXX |
| EV/EBITDA | 102.2x | XXX | 16.7x | XXX | XXX | XXX |
| EV/EBIT | -30.5x | XXX | -6.9x | XXX | XXX | XXX |
| EV/Gross Profit | 6.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -11.4x | XXX | -38.9x | XXX | XXX | XXX |
| EV/FCF | -13.2x | XXX | -6.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialValneva's last 12 month revenue growth is 20%
Valneva's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Valneva's rule of 40 is -18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Valneva's rule of X is 53% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Valneva and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | -649% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -18% | XXX | 39% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 53% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 31% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 44% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 88% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Valneva acquired XXX companies to date.
Last acquisition by Valneva was XXXXXXXX, XXXXX XXXXX XXXXXX . Valneva acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Valneva founded? | Valneva was founded in 1999. |
| Where is Valneva headquartered? | Valneva is headquartered in France. |
| How many employees does Valneva have? | As of today, Valneva has 713 employees. |
| Who is the CEO of Valneva? | Valneva's CEO is Mr. Thomas Lingelbach. |
| Is Valneva publicy listed? | Yes, Valneva is a public company listed on PAR. |
| What is the stock symbol of Valneva? | Valneva trades under VLA ticker. |
| When did Valneva go public? | Valneva went public in 2007. |
| Who are competitors of Valneva? | Similar companies to Valneva include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Valneva? | Valneva's current market cap is $535M |
| What is the current revenue of Valneva? | Valneva's last 12 months revenue is $199M. |
| What is the current revenue growth of Valneva? | Valneva revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of Valneva? | Current revenue multiple of Valneva is 3.0x. |
| Is Valneva profitable? | Yes, Valneva is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Valneva? | Valneva's last 12 months EBITDA is $5.9M. |
| What is Valneva's EBITDA margin? | Valneva's last 12 months EBITDA margin is 3%. |
| What is the current EV/EBITDA multiple of Valneva? | Current EBITDA multiple of Valneva is 102.2x. |
| What is the current FCF of Valneva? | Valneva's last 12 months FCF is -$45.5M. |
| What is Valneva's FCF margin? | Valneva's last 12 months FCF margin is -23%. |
| What is the current EV/FCF multiple of Valneva? | Current FCF multiple of Valneva is -13.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
